Here, an international and highly distinguished team of authors leads readers from the principles of programmed cell death to the role of apoptosis in cancer development and emerging treatment strategies. Divided into two distinct parts, the first focuses on apoptosis signaling, covering in depth such topics as mitochondria, effector systems, the Bcl-2 family, IAPs, survival pathways, tumor suppressor genes, modulators, lysosomes and phagocytosis. The second section goes on to analyze apoptosis in cancer and cancer therapy, with a detailed look at model systems, molecular diagnosis, cellular stress, DNA damage and repair, molecular targets and therapeutic aspects. With its strong focus on recent developments in cancer therapy, this book is aimed at oncologists, molecular and cell biologists, biochemists, and those working in the pharmaceutical and biotechnological industries.
Rezensionen / Stimmen
"...this excellent book on research in cell death is on the forefront of modern molecular oncology." (New England Journal of Medicine, December 21, 2006)
Auflage
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Onkologen, Molekularbiologen, Biochemiker, Pharmaindustrie
Illustrationen
98
23 s/w Tabellen, 98 s/w Abbildungen
Maße
Höhe: 24.5 cm
Breite: 18 cm
Dicke: 6.7 cm
Gewicht
ISBN-13
978-3-527-31237-5 (9783527312375)
Schweitzer Klassifikation
Klaus-Michael Debatin studied medicine at the universities of Ulm, Freiburg and Heidelberg, and was awarded his doctorate in 1979. In 1990 he gained his lecturing qualification and from 1991 to 1994 was a recipient of a Heisenberg scholarship awarded by the German Research Foundation. In 1994, he became head of the hematology/oncology division at the University Children's Hospital, Heidelberg and, one year after this, head of the molecular oncology/pediatrics division at the German National Cancer Center in Heidelberg. Since 1997, Klaus-Michael Debatin has been professor and chairman of the Department of Pediatrics at the University of Ulm.
Simone Fulda studied medicine at the universities of Cologne, Boston, San Francisco, Phoenix and Dublin, gaining her doctorate in 1995. After training at the University Children's Hospital at Heidelberg and Ulm, she got her board certificate in pediatrics in 2001. In the same year, Dr. Fulda earned her lecturing qualification and since 2002 she has been a holder of a Heisenberg scholarship, awarded by the German Research Foundation.
Herausgeber*in
University Childrens's Hospital Ulm, Germany
University Childrens's Hospital Ulm, Germany
Volume I. Apoptosis signaling
I.1. Death receptor:
-CD95 signaling
-The TRAIL receptor-ligand system
-TNF-induced cell death
-cFLIP
-Dependence receptors and apoptosis
I.2. Mitochondria:
-Role of mitochondrial proteins in apoptosis
-Omi/HtrA2
-Apoptosis inducing factor (AIF)
I.3. Effector systems:
-Caspases
-Apoptosome
I.4. Bcl-2 family:
-Bcl-2 family proteins
-Bax, Bak and Bid
-Puma/Noxa
I.5. IAPs:
-Inhibitor of apoptosis proteins (IAPs)
-Targeting the survivin pathway
I.6. Survival pathways:
-NFkB
-Pi3K/AKT
-Ras/Raf
I.7. Oncogenes/Tumor suppressor genes:
-P53
-P73
-RB
I.8. Modulators:
-Calcium signaling
I.9. Lysosomes and non-apoptotic pathways
I.10. Phagocytosis/ Clearance:
-Phagocytosis of apoptotic cells
-Clearance of apoptotic cells
Volume II. Apoptosis in cancer and cancer therapy
II.1. Models systems:
-Mouse models
II.2. Molecular diagnosis:
-Molecular imaging in cancer research
-Microarrays
II.3. Cellular stress, DNA damage & repair:
-Stress signaling in cancer
-Hypoxia in cancer
-DNA damage-induced apoptosis
-DNA repair
II.4. Molecular targets and therapeutic aspects:
-Therapeutic Modulation of Apoptosis
-Targeting caspases in cancer
-Cancer therapy by reactivation of the p53 apoptosis pathway
-Small molecule inhibitors of IAPs
-Targeting HSP90
-Targeting the PI3K/Akt pathway
-Ceramide Signaling
-HDAC inhibitors
-Exploiting apoptosis pathways for glioblastoma therapy
-Radiation therapy and apoptosis
-Tumor angiogenesis
